Journal of Molecular Histology

, Volume 37, Issue 8, pp 327–332

High expression of APOBEC3G in patients infected with hepatitis C virus

  • Yoshihiro Komohara
  • Hirohisa Yano
  • Shigeki Shichijo
  • Kunitada Shimotohno
  • Kyogo Itoh
  • Akira Yamada
Original Paper

DOI: 10.1007/s10735-006-9059-0

Cite this article as:
Komohara, Y., Yano, H., Shichijo, S. et al. J Mol Hist (2006) 37: 327. doi:10.1007/s10735-006-9059-0

Abstract

APOBEC3G (an apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G; also known as CEM15), a member of the APOBEC family, which possesses cytidine deaminase activity that causes C/G to T/A transition mutations in virus genomes such as human immunodeficiency virus 1 and hepatitis B virus, is reported to play an important role in host-defense mechanisms. However, APOBEC3G expression in patients infected with chronic hepatitis C virus (HCV), of which there are currently more than 170 million worldwide, has not yet been well studied. We investigated this issue herein, and demonstrated an increased expression of APOBEC3G in both hepatocytes and lymphocytes of chronic hepatitis patients infected with HCV. Transfection of the NS5A gene, but not any other non-structural protein genes of HCV tested, to the hepatocellular carcinoma cell line enhanced APOBEC3G expression. Incubation of the cells with interferon also resulted in the augmentation. These results may provide new insight into the pathogenesis of chronic HCV infection.

Keywords

APOBEC3GHCVHepatocytesNS5AInterferon

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Yoshihiro Komohara
    • 1
    • 2
  • Hirohisa Yano
    • 3
  • Shigeki Shichijo
    • 1
  • Kunitada Shimotohno
    • 4
  • Kyogo Itoh
    • 1
  • Akira Yamada
    • 1
    • 2
  1. 1.Department of ImmunologyKurume University School of MedicineKurumeJapan
  2. 2.Cancer Vaccine Development DivisionResearch Center for Innovative Cancer Therapy, and Center of the 21st Century Center of Excellence Program for Medical Science, Kurume UniversityKurume, FukuokaJapan
  3. 3.Department of PathologyKurume University School of MedicineKurumeJapan
  4. 4.Department of Viral OncologyInstitute for Virus Research, Kyoto UniversityKyotoJapan